Clinical Report: 2026 ASCO Prostate Cancer Highlights
Overview
The 2026 ASCO Prostate Cancer Highlights provide updates on clinical trials and treatment advancements in prostate cancer. Notable findings include perioperative apalutamide and the addition of talazoparib to enzalutamide in specific patient populations.
Background
Prostate cancer is a significant health concern, with recent clinical trials introducing new therapies and strategies aimed at improving patient outcomes in high-risk and metastatic cases.
Data Highlights
No specific numerical data provided in the source material.
Key Findings
- The PROTEUS trial demonstrated that perioperative apalutamide plus ADT significantly improved major pathologic response and metastasis-free survival compared to placebo plus ADT.
- The addition of talazoparib to enzalutamide has shown benefits in metastatic androgen pathway modulation-sensitive prostate cancer.
- Guidelines from NCCN for 2026 include the removal of the 'very-low-risk' category and updates on imaging and treatment algorithms.
- EAU's 2026 update emphasizes a preference for transperineal biopsy routes due to infection concerns.
- AUA/ASTRO released a 2026 amendment to the Clinically Localized Prostate Cancer Guideline reflecting new evidence.
Clinical Implications
Healthcare professionals should be aware of the latest clinical trial results and guideline updates.
Conclusion
The 2026 ASCO Prostate Cancer Highlights present findings from recent clinical trials and guideline updates in the management of prostate cancer.
Related Resources & Content
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 2026 -- 2026 ASCO Prostate Cancer Highlights
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 2026 -- Prostate Cancer Highlights presented by Michael Serzan, MD
- Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, 2026 -- Prostate Cancer Conference Highlights from ASCO GU 2025
- NCCN Prostate Cancer Guidelines, 2026 -- NCCN Prostate Cancer (Version 2.2026)
- EAU Guidelines on Prostate Cancer, 2026 -- EAU Guidelines
- AUA/ASTRO Guideline Amendment, 2026 -- Clinically Localized Prostate Cancer
- AUA/SUO Advanced Prostate Cancer Guideline, 2026 -- Key updates and clinical FAQs
- Journal of Clinical Oncology, 2026 -- PROTEUS Trial
- dana-farber — Prostate Cancer Highlights from ASCO 2025
- ASCO 2026 Prostate Cancer Highlights
- https://www.oregon.gov/oha/HPA/DSI-HERC/MembersOnly/7.8f%20NCCN%202.2026%20prostate.pdf
- https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2026_2026-03-14-104356_ixav.pdf
- Clinically Localized Prostate Cancer: AUA/ASTRO Guideline Amendment (2026) | Journal of Urology
- 2026 AUA/SUO Advanced Prostate Cancer Guideline: Key updates and clinical FAQs | Urology Times
- Perioperative (neoadjuvant and adjuvant) apalutamide (APA) + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT with radical prostatectomy (RP) in high-risk localized or locally advanced prostate cancer (HR LPC/LAPC): Final analysis of the PROTEUS phase 3 study. | Journal of Clinical Oncology
- PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer - The ASCO Post
- Addition of Talazoparib to Enzalutamide in Metastatic Androgen Pathway Modulation–Sensitive Prostate Cancer - The ASCO Post
- FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer | FDA
- Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study - PubMed
- Shifting 177Lu-PSMA-617 upstream in mCRPC: A meta-analysis of randomized trials stratified by taxane exposure. | Journal of Clinical Oncology
- XALience: A phase 3, open-label, multicenter, randomized study of xaluritamig plus abiraterone vs investigator’s choice in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer. | Journal of Clinical Oncology
- IDeate-Prostate01: A phase 3, randomized, open-label study of ifinatamab deruxtecan versus docetaxel in participants with previously treated metastatic castration-resistant prostate cancer. | Journal of Clinical Oncology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
